SCHEMBL6616883

SCHEMBL6616883

CCCc1ccc(S(=O)(=O)Nc2ccsc2-c2c(F)cccc2Cl)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.40
MEN1 O00255 1/20 0.40
TSHR P16473 1/20 0.40
KMT2A Q03164 1/20 0.40
FFAR1 O14842 1/20 0.39
METAP2 P50579 1/20 0.39
CCR2 P41597 1/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C19 P33261 1/20 0.39
MAPT P10636 1/20 0.38
ATM Q13315 1/20 0.38
GLA P06280 1/20 0.37
AKT1 P31749 7/20 0.36
PKM P14618 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
PDPK1 O15530 1/20 0.35
ABCB11 O95342 1/20 0.35
AKT2 P31751 1/20 0.35
GAB1 Q13480 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20899649 0.84 HSD11B1 (0.40) CCR2SCN1ASCN5ASCN8A
SCHEMBL6613711 0.83 METAP2 (0.44) FFAR4MEN1TSHRKMT2AMETAP2
SCHEMBL6612760 0.82 FFAR4 (0.47) FFAR4MEN1TSHRKMT2AFFAR1
SCHEMBL6612066 0.81 FFAR4 (0.40) FFAR4MEN1TSHRKMT2AFFAR1
SCHEMBL6693272 0.78 CA2 (0.51) FFAR4MEN1TSHRKMT2AMETAP2
SCHEMBL2762549 0.78 RORC (0.51) MEN1KMT2A
SCHEMBL5831074 0.77 AKT1 (0.49) MEN1KMT2AATMAKT1PKM
SCHEMBL5830985 0.76 AKT1 (0.40) FFAR4FFAR1GLAAKT1PDPK1
SCHEMBL6612001 0.74 PFKFB3 (0.41) TSHRCCR2MAPTPKMSCN1A
SCHEMBL31681357 0.74 KMT2A (0.61) FFAR4MEN1TSHRKMT2AMETAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1633428-A 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors BIOVITRUM AB (SE) 2005-06-29 CN claimed
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO claimed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
CN-1633428-A 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors BIOVITRUM AB (SE) 2005-06-29 CN disclosed
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO disclosed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 FFAR4 3173/4885MEN1 770/4885TSHR 4127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.